Recruiting studies: Pmmr Mss Locally Advanced Rectal Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07448142 SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Ca
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06864013 Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab a
Phase 2 · 1 location(s) · Dechang Diao · NCT07005570 Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
Phase 2 · 1 location(s) · Zhejiang University · NCT05731726 Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT)
Phase 2 · 1 location(s) · Shandong Cancer Hospital and Institute · NCT07026422 A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor a
Phase 2 · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT07669220 Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
Phase 2 · 1 location(s) · Seventh Medical Center of PLA General Hospital · NCT07458529 Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT07528209 Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIF
Phase 2 · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT06923345 mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC
Phase 3 · 1 location(s) · Jun Huang · NCT06791512 Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MS
Phase 2 · 1 location(s) · Dechang Diao · NCT07674732 A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant T
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT07527026 Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06911684

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.